Prevalence and predictors of clinically significant statin–drug interactions among Yemeni patients taking statins for primary and secondary prevention of cardiovascular disease

References

• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10(8):453–464.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):e177–e232. 2019
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350.
   PubMed Web of Science ®Google Scholar
• Unit ES. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
   PubMedGoogle Scholar
• Cerqueira NM, Oliveira EF, Gesto DS, et al. Cholesterol biosynthesis: a mechanistic overview. Biochemistry. 2016;55(39):5483–5506.
   PubMedGoogle Scholar
• Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007;40(9–10):575–584.
   PubMed Web of Science ®Google Scholar
• Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016;32(6):631–639.
   PubMed Web of Science ®Google Scholar
• Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. Jama. 2016;316(19):2008–2024.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Simic I, Reiner Z. Adverse effects of statins – myths and reality. Curr Pharm Des. 2015;21(9):1220–1226.
   PubMed Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8):S52–S60.
   PubMedGoogle Scholar
• Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28(1):26–35.
   PubMedGoogle Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–1022.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11(6):933–946.
   PubMed Web of Science ®Google Scholar
• Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–e495.
   PubMed Web of Science ®Google Scholar
• Hammoud A, Shapiro MD. Drug interactions: what are important drug interactions for the most commonly used medications in preventive cardiology? Med Clin North Am. 2022;106(2):389–399.
   PubMedGoogle Scholar
• Valladales-Restrepo LF, Medina-Morales DA, Giraldo-Giraldo C, et al. Prescription of statins and pharmacokinetic interactions in Colombian patients. Expert Opin Drug Metab Toxicol. 2021;17(5):627–634.
   PubMed Web of Science ®Google Scholar
• Yan M-M, Wu S-S, Ying Y-Q, et al. Safety assessment of concurrent statin treatment and evaluation of drug interactions in China. SAGE Open Med. 2018;6:2050312118798278.
   Google Scholar
• Lee KJ, Kim KR, Seong JM, et al. Evaluation of potential drug-drug interactions in patients taking HMG CoA-reductase inhibitors. Korean J Clin Pharm. 2020;30(1):31–35.
   Google Scholar
• Zhelyazkova-Savova M, Gancheva S, Sirakova V. Potential statin-drug interactions: prevalence and clinical significance. Springerplus. 2014;3(1):168–168.
   PubMedGoogle Scholar
• Egger SS, Bravo AER, Hess L, et al. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs & Aging. 2007;24(5):429–440.
   PubMed Web of Science ®Google Scholar
• Morival C, Westerlynck R, Bouzillé G, et al. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. Eur J Clin Pharmacol. 2018;74(4):525–534.
   PubMed Web of Science ®Google Scholar
• Bakhai A, Rigney U, Hollis S, et al. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf. 2012;21(5):485–493.
   PubMed Web of Science ®Google Scholar
• Ming EE, Davidson MH, Gandhi SK, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol. 2008;2(6):453–463.
   PubMed Web of Science ®Google Scholar
• Daniel WW, Cross CL. Biostatistics: a foundation for analysis in the health sciences. Hoboken (NJ): Wiley; 2018.
   Google Scholar
• Lexi-Interact™ online [cited 20/10/2021]. Available from: http://www.uptodate.com/crlsql/interact/frameset.jsp.
   Google Scholar
• Kheshti R, Aalipour M, Namazi S. A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257–263.
   PubMed Web of Science ®Google Scholar
• Akbar Z, Rehman S, Khan A, et al. Potential drug–drug interactions in patients with cardiovascular diseases: findings from a prospective observational study. J Pharm Policy Pract. 2021;14(1):1–9.
   PubMedGoogle Scholar
• Yang BR, Seong J-M, Choi N-K, et al. Co-medication of statins with contraindicated drugs. PLoS One. 2015;10(5):e0125180.
   PubMed Web of Science ®Google Scholar
• Santos-Díaz G, Pérez-Pico AM, Suárez-Santisteban MÁ, et al. Prevalence of potential drug–drug interaction risk among chronic kidney disease patients in a Spanish Hospital. Pharmaceutics. 2020;12(8):713.
   PubMed Web of Science ®Google Scholar
• Patel RI, Beckett RD. Evaluation of resources for analyzing drug interactions. J Med Libr Assoc. 2016;104(4):290–295.
   PubMed Web of Science ®Google Scholar
• Damiani I, Corsini A, Bellosta S. Potential statin drug interactions in elderly patients: a review. Expert Opin Drug Metab Toxicol. 2020;16(12):1133–1145.
   PubMed Web of Science ®Google Scholar
• Zawiah M, Al-Ashwal FY, Saeed RM, et al. Assessment of healthcare system capabilities and preparedness in Yemen to confront the novel coronavirus 2019 (COVID-19) outbreak: a perspective of healthcare workers. Front Public Health. 2020;8:419.
   PubMed Web of Science ®Google Scholar
• Al-Worafi YM. Drug safety in Yemen. Drug safety in developing countries. Cambridge (MA): Elsevier; 2020. p. 391–405.
   Google Scholar
• Al-Ashwal FY, Sulaiman SAS, Ghadzi SMS, et al. Knowledge, attitude, perceived barriers, and practices among pharmacists regarding risk assessment of cardiovascular disease: a cross-sectional study in Yemen. Curr Med Res Opin. 2022;38(3):451–425.
   PubMedGoogle Scholar
• Nusair MB, Al-Azzam SI, Arabyat RM, et al. The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan. Saudi Pharm J. 2020;28(2):155–160.
   PubMed Web of Science ®Google Scholar
• Patel C, Thompson C, Copley-Harris M, et al. Sitagliptin and simvastatin interaction causing rhabdomyolysis and AKI. Case Rep Med. 2019;2019:2601537.
   PubMedGoogle Scholar
• DiGregorio RV, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy: J Hum Pharmacol Drug Ther. 2009;29(3):352–356.
   Google Scholar
• Buttar RS, Batra J, Kreimerman J, et al. Rhabdomyolysis and AKI with atorvastatin and sitagliptin use in the setting of low 25-hydroxyvitamin D levels. J Gen Intern Med. 2017;32(10):1156–1159.
   PubMedGoogle Scholar
• Bhome R, Penn H. Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. Diabet Med. 2012;29(5):693–694.
   PubMedGoogle Scholar
• Antonazzo IC, Poluzzi E, Forcesi E, et al. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. Acta Diabetol. 2020;57(1):71–80.
   PubMed Web of Science ®Google Scholar
• De Schryver N, Wittebole X, Van den Bergh P, et al. Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine coadministration. Case Rep Nephrol. 2015;2015:761393.
   PubMedGoogle Scholar
• Sawant R. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. J Popul Ther Clin Pharmacol. 2009;16(1):e78–e79.
   Google Scholar
• Goldie FC, Brogan A, Boyle JG. Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis. Case Reports. 2016;2016:bcr2016216048.
   PubMedGoogle Scholar
• Irfan F, Karim SI. Co-prescription of ciprofloxacin and statins; a dangerous combination: case report. J Pak Med Assoc. 2020;70(7):1272–1274.
   PubMedGoogle Scholar
• Qian Q, Nasr SH, Akogyeram CO, et al. Myoglobin-associated acute kidney injury in the setting of ciprofloxacin administration. Am J Kidney Dis. 2012;59(3):462–466.
   PubMedGoogle Scholar
• Martin PD, Schneck DW, Dane AL, et al. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin. 2008;24(4):1231–1235.
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet. 2007;370(9601):1781–1790.
   PubMed Web of Science ®Google Scholar
• Engell AE, Svendsen AL, Lind BS, et al. Drug-drug interaction between warfarin and statins: a Danish Cohort study. Br J Clin Pharmacol. 2021;87(2):694–699.
   PubMedGoogle Scholar
• Pinheiro LF, França CN, Izar MC, et al. Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. Int J Cardiol. 2012;158(1):125–129.
   PubMed Web of Science ®Google Scholar
• Hwang NK, Park JS, Cha KS, et al. Hepatotoxicity associated with a short course of rosuvastatin. Chin Med J. 2015;128(12):1693–1694.
   PubMedGoogle Scholar
• Ning C, Su S, Li J, et al. Evaluation of a clinically relevant drug-drug interaction between rosuvastatin and clopidogrel and risk of hepatotoxicity. Front Pharmacol. 2021;12:2159.
   Google Scholar
• Ben Salem C, Sahnoun D, Slim R, et al. Atorvastatin and sildenafil interaction-induced rhabdomyolysis. Ann Pharmacother. 2020;54(10):1047–1048.
   PubMedGoogle Scholar
• Pennisi G, Vacante M, Russo C, et al. Rhabdomyolysis induced by rosuvastatin and sildenafil. South Med J. 2010;103(10):1052–1054.
   PubMedGoogle Scholar
• Gutierrez CA. Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis? Am Fam Physician. 2001;63(4):636–637.
   PubMedGoogle Scholar
• Bai Y, Murakami H, Iwasa M, et al. Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP‐sensitive potassium channels. Clin Exp Pharmacol Physiol. 2011;38(10):658–665.
   PubMedGoogle Scholar
• Kim J-R, Jung JA, Kim S, et al. Effect of cilostazol on the pharmacokinetics of simvastatin in healthy subjects. Biomed Res Int. 2019;2019:1365180.
   PubMed Web of Science ®Google Scholar
• Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469–491.
   PubMed Web of Science ®Google Scholar
• Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45(4):422–433.
   PubMed Web of Science ®Google Scholar
• Correa D, Landau M. Ranolazine-induced myopathy in a patient on chronic statin therapy. J Clin Neuromuscul Dis. 2013;14(3):114–116.
   PubMedGoogle Scholar
• Rifkin SI. Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report. Medscape J Med. 2008;10(11):264.
   PubMedGoogle Scholar
• Hylton AC, Ezekiel TO. Rhabdomyolysis in a patient receiving ranolazine and simvastatin. Am J Health Syst Pharm. 2010;67(21):1829–1831.
   PubMedGoogle Scholar
• Ginanneschi F, Volpi N, Giannini F, et al. Rhabdomyolysis in an elderly multitreated patient: multiple drug interactions after statin withdrawal. J Neurol Sci. 2014;336(1–2):284–287.
   PubMed Web of Science ®Google Scholar
• Kassardjian CD, Tian X, Vladutiu G, et al. Myopathy during treatment with the antianginal drug ranolazine. J Neurol Sci. 2014;347(1–2):380–382.
   PubMedGoogle Scholar
• Ranexa (ranolazine) [prescribing information]. [cited November 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021526s029lbl.pdf.
   Google Scholar
• Ucar M, Neuvonen M, Luurila H, et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol. 2004;59(12):879–882.
   PubMed Web of Science ®Google Scholar
• Bullman J, Nicholls A, Van Landingham K, et al. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia. 2011;52(7):1351–1358.
   PubMed Web of Science ®Google Scholar
• Khandwala HM. Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin. South Med J. 2006;99(12):1385–1388.
   PubMedGoogle Scholar
• Murphy M, Dominiczak M. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J. 1999;75(884):359–361.
   PubMedGoogle Scholar
• Mellal AA, Hussain N, Said AS. The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies. Ther Clin Risk Manag. 2019;15:921–936.
   PubMedGoogle Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565–581.
   PubMed Web of Science ®Google Scholar
• Page S, Yee K. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. Intern Med J. 2014;44(7):690–693.
   PubMedGoogle Scholar
• Toolis M, Banakh I, Botha J. Rhabdomyolysis requiring emergency dialysis as a consequence of simultaneous administration of simvastatin and clarithromycin. Int J Case Rep. 2020;4:147–147.
   Google Scholar
• Wagner J, Suessmair C, Pfister H-W. Rhabdomyolysis caused by co-medication with simvastatin and clarithromycin. J Neurol. 2009;256(7):1182–1183.
   PubMedGoogle Scholar
• Ezad S, Cheema H, Collins N. Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction. Oxf Med Case Reports. 2018;2018(3):omx104.
   PubMedGoogle Scholar
• Page S. Clarithromycin/ezetimibe/simvastatin interaction. Reactions. 2014;1513:14–19.
   Google Scholar
• Hirota T, Ieiri I. Drug-drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol. 2015;11(9):1435–1447.
   PubMed Web of Science ®Google Scholar